SUPN Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 35.57%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.

Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.75%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.57 which suggests that it could grow by 41.45%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Supernus Pharmaceuticals, Inc..

Supernus Pharmaceuticals, Inc. has a beta of 0.706, which suggesting that the stock is 29.381% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.455%.

Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.27x versus 5.37x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 81.15%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.75%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $289.10 which suggests that it could grow by 6%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Supernus Pharmaceuticals, Inc. has a beta of 0.706, which suggesting that the stock is 29.381% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Krystal Biotech, Inc.'s PE ratio is 40.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.27x versus 21.81x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of -19.69%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Moderna, Inc.'s return on equity of -30.18%.

Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.75%. On the other hand Moderna, Inc. has an analysts' consensus of $38.80 which suggests that it could fall by -5.39%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Moderna, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Moderna, Inc..

Supernus Pharmaceuticals, Inc. has a beta of 0.706, which suggesting that the stock is 29.381% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is higher than Moderna, Inc.'s net income of -$200M. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.27x versus 7.12x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -23.49% compared to Supernus Pharmaceuticals, Inc.'s net margin of 34.76%. Supernus Pharmaceuticals, Inc.'s return on equity of -1.84% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.

Supernus Pharmaceuticals, Inc. has a consensus price target of $61.33, signalling upside risk potential of 18.75%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $514.32 which suggests that it could grow by 7.62%. Given that Supernus Pharmaceuticals, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Supernus Pharmaceuticals, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Supernus Pharmaceuticals, Inc. has a beta of 0.706, which suggesting that the stock is 29.381% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.303, suggesting its less volatile than the S&P 500 by 69.725%.

Supernus Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals, Inc. quarterly revenues are $192.1M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. Supernus Pharmaceuticals, Inc.'s net income of -$45.1M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, Supernus Pharmaceuticals, Inc.'s price-to-earnings ratio is 41.17x while Vertex Pharmaceuticals, Inc.'s PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals, Inc. is 4.27x versus 10.55x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.